MDT-AP-1162
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 12.96
- os_event
- true
- age_years
- 8.7
- sex
- F
- new_clusters
- C4
- umap1_2d
- 3.001739716
- umap2_2d
- 4.80493581
- umap1_3d
- 0.726467568
- umap2_3d
- -0.193188072
- umap3_3d
- -1.46086183
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- SPERMATOGENESIS+0.300
- E2F_TARGETS+0.290
- G2M_CHECKPOINT+0.260
- PANCREAS_BETA_CELLS+0.240
- KRAS_SIGNALING_DN+0.220
- ALLOGRAFT_REJECTION+0.050
- ESTROGEN_RESPONSE_LATE-0.010
- PEROXISOME-0.030
- MYC_TARGETS_V2-0.040
- DNA_REPAIR-0.050
Top 10 suppressed
- ANGIOGENESIS-0.470
- UV_RESPONSE_DN-0.450
- NOTCH_SIGNALING-0.430
- PROTEIN_SECRETION-0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- UNFOLDED_PROTEIN_RESPONSE-0.390
- IL6_JAK_STAT3_SIGNALING-0.380
- MITOTIC_SPINDLE-0.340
- TNFA_SIGNALING_VIA_NFKB-0.340
- HYPOXIA-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR25617852 | — | B | 0.916 |
| 2 | SRR1797291 | — | cohortSC | 0.873 |
| 3 | MDT-AP-1141 | Med | Medulloblastoma | 0.873 |
| 4 | TCGA-44-7660-01A-11R-2066-07 | — | cohortMD1 | 0.870 |
| 5 | TCGA-BB-4224-01A-01R-1436-07 | — | — | 0.869 |
| 6 | TCGA-CN-5374-01A-01R-1436-07 | — | — | 0.869 |
| 7 | SRR25617851 | — | B | 0.868 |
| 8 | TCGA-E9-A3HO-01A-11R-A213-07 | — | B | 0.868 |
| 9 | SRR25617831 | — | D | 0.867 |
| 10 | TCGA-KQ-A41O-01A-12R-A352-07 | — | — | 0.866 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 6 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.290 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.050 | Idelalisib | — uncovered |